Tag: studies

Fintiv: More Work, Less Quality

When the Patent Trial and Appeal Board (PTAB or “Board”) first decided the IPR that led to the Fintiv rule, it justified its decision on the basis of “balanc[ing] considerations such as system e...

Fintiv Analysis Proves That Fintiv Is Being Used To Leave Likely Invalid Patents In Force

A recently released study from Unified Patents has put numbers to the sense many patent attorneys already had—the Patent Trial and Appeal Board is spending a lot of time on Fintiv discretionary deni...

The ITC In 2020: Anything But Typical

With the American republic having just had its 245th birthday, let’s take a look at an agency that’s charged with regulating trade with foreign countries, encouraging American industries, and prot...

Discretionary Denials at the PTAB Continue to Rise, Benefit NPEs

According to new data from Unified Patents, the rise in discretionary denials at the PTAB is showing no signs of slowing down.  In 2019, there were 6 denials based on co-pending litigation (so-ca...

New Study Shows That IPR Delivers An Economic Benefit, Even If The District Court Doesn’t Stay Litigation

New research from the Perryman Group shows that inter partes review (IPR) is economically beneficial, even if co-pending district court litigation isn’t stayed.  The Perryman study, commissione...

New Report Confirms IPR Has Had Significant Positive Impacts On U.S. Industry

A recent report, prepared by economists at the Perryman Group, confirms what has long been stated to be the case—inter partes review (IPR) has positively impacted the U.S. economy.   In...

CCIA Letter to Senate Judiciary IP Subcommittee Members On Questionable Studies

At last week’s Senate Judiciary IP Subcommittee hearing, questioners referenced two studies.  The first, on multiple IPR petitions, was conducted by Steve Carlson and Ryan Schultz of Robins Kap...

FTC Hearings #4: Patents, Intellectual Property, and Innovation

This post has been cross-posted to DisCo. Last week, the FTC held the fourth in its set of hearings focusing on “Competition and Consumer Protection in the 21st Century.”  The first day focused ...

Additional Studies Show IPR Is Not A Threat To Hatch-Waxman Process

Over a year ago, I took a look at a study of the success rate for inter partes reviews (IPRs) of pharmaceutical patents.  That study showed that drug and biologic patents are significantly more likel...

Subscribe to Patent Progress

No spam. Unsubscribe anytime.